Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ParkerVision, Inc.'s SEC filings document an OTCQB-traded Florida corporation focused on proprietary RF technologies, wireless applications, licensing, and patent enforcement. Its 8-K filings report operating results, legal and appellate developments involving patent claims, and material events that affect the company's capital structure and disclosure record.
The filing record also covers registered direct common stock offerings under a Form S-3 shelf registration statement, exchanges of convertible promissory notes for common stock, unregistered equity issuance disclosures, and executive compensation arrangements under the company's long-term incentive plan. These documents address governance approvals, share-based awards, financing terms, and risk references tied to patent proceedings and funding activity.
ParkerVision, Inc. has filed a prospectus supplement that continues to permit the resale by selling stockholders of up to 12,800,000 shares of common stock previously registered under its shelf program. These shares consist of up to 7,800,000 shares issuable upon conversion of, or payment of interest on, convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant.
The company will not receive proceeds from resale of these shares, but could receive up to $800,000 in gross proceeds if the warrant is exercised for cash, which it expects to use for patent enforcement, working capital, and general corporate purposes. The attached Form 8-K discloses that ParkerVision also completed a separate registered offering of 16,481,579 common shares to accredited investors for an aggregate purchase price of $3,461,132, with no commissions or fees paid.
ParkerVision, Inc. completed a primary offering of 16,481,579 shares of common stock to accredited investors at $0.21 per share, raising gross proceeds of $3,461,132. The shares were sold directly under subscription agreements without underwriters or placement agents, and the deal closed on November 24, 2025.
The company plans to use the cash for working capital, general corporate purposes, and litigation fees and expenses, which align with its IP-enforcement focused business model. On a pro forma basis as of September 30, 2025, cash would increase from $901,000 to $5,470,000, and total shareholders’ deficit would narrow from $(49.8) million to $(45.2) million, though the balance sheet remains highly leveraged.
The offering price creates meaningful dilution. Pro forma as adjusted net tangible book value moves from $(0.39) to $(0.32) per share, implying an immediate dilution of $0.53 per share to new investors buying at $0.21. The company continues to highlight substantial risks, including a limited OTCQB trading market, a need for additional capital, and going concern language in its audited financial statements.
ParkerVision, Inc. (PRKR) reported that on November 24, 2025 it completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132. The shares were issued under the company’s existing shelf registration statement on Form S-3 and a prospectus supplement containing the final terms of the offering.
The company conducted this transaction directly, engaging no underwriters, placement agents, brokers, or finders and paying no commissions or fees, so the full purchase price goes to ParkerVision. The company also disclosed that it issued a press release announcing the closing of the transaction, which is included as an exhibit.
ParkerVision, Inc. entered into subscription agreements with accredited investors to sell 16,481,579 shares of common stock at $0.21 per share, for aggregate gross proceeds of approximately $3,461,132. The transaction is structured as a registered direct offering made by the company without an underwriter or placement agent.
The shares are being offered under ParkerVision’s existing shelf registration statement on Form S-3, and closing is expected to occur on November 24, 2025. Legal opinions and the form of subscription agreement are being filed as exhibits to support the issuance and sale of the securities.
ParkerVision director Lewis H. Titterton Jr. filed a Schedule 13D reporting his beneficial ownership in PRKR. As of November 17, 2025, he beneficially owns 8,829,430 shares of common stock, or approximately 6.98% of the 126,311,303 shares outstanding disclosed in a recent prospectus supplement. This total includes 251,260 shares underlying stock options, warrants and restricted stock awards that are exercisable or will vest within 60 days.
Titterton agreed on November 14, 2025 to purchase 4,761,905 shares at $0.21 per share under a Subscription Agreement, with closing on November 17, 2025, and he exercised 800,000 non-qualified stock options at an average exercise price of $0.185 per share. He states he holds the shares for investment purposes and may buy more, hold, sell, or distribute shares over time based on market conditions, the company’s performance, liquidity needs and other factors, subject to company policies including its insider trading policy.
ParkerVision, Inc. (PRKR) reported an insider share purchase by a company director. The reporting person acquired 4,761,905 shares of common stock at $0.21 per share for an aggregate purchase price of $1,000,000. The price matched the last sale price of ParkerVision common stock on November 14, 2025, and the transaction closed on November 17, 2025. Following this purchase, the director beneficially owns 8,578,170 shares directly. The purchase was executed under an existing shelf registration statement on Form S-3 that was declared effective on May 28, 2025, and was reviewed and approved by the disinterested members of the board in accordance with Florida corporate law.
ParkerVision, Inc. completed a registered direct offering of 4,761,905 shares of common stock to board member Lewis H. Titterton, Jr. for $1,000,000, priced at $0.21 per share, equal to the last reported OTCQB sale price on November 14, 2025. The company received the full amount with no underwriting or placement fees.
Shares outstanding increase from 121,549,398 to 126,311,303, and the transaction causes immediate dilution, with pro forma net tangible book value rising from approximately $(0.42) to $(0.40) per share. Management plans to use the net proceeds for working capital and other general corporate purposes, including litigation fees and expenses, as ParkerVision continues to focus on enforcing its RF patent portfolio.
ParkerVision, Inc. (PRKR) completed a registered offering of 4,761,905 shares of common stock for total proceeds of $1,000,000. The shares were sold on November 17, 2025 to company director Lewis H. Titterton, Jr. at $0.21 per share, matching the last reported sale price of the stock on the OTCQB Venture Market on November 14, 2025, under a subscription agreement dated that day. The issuance was made from ParkerVision’s Form S-3 shelf registration statement and a prospectus supplement that set the final terms. The company did not use underwriters or placement agents and paid no commissions or fees in connection with this transaction.
ParkerVision, Inc. entered into a subscription agreement for 4,761,905 shares of its common stock with director Lewis H. Titterton, Jr. for a total of $1,000,000. The shares are priced at $0.21 per share, matching the last reported sale price of the stock on the OTCQB Venture Market on November 14, 2025. The transaction is being conducted directly by the company without an underwriter, under an existing Form S-3 shelf registration. Because the buyer is a board member, the deal was reviewed and approved by disinterested directors under Florida corporate law, with closing expected on or before November 18, 2025.
ParkerVision, Inc. has filed a prospectus supplement that allows selling shareholders to resell up to 9,387,500 shares of common stock, primarily from previously issued shares and shares underlying convertible notes and options. The company will not receive proceeds from these resales, and would receive only up to $42,620 if certain options are exercised for cash.
Attached to the supplement is ParkerVision’s latest quarterly report, showing a net loss of about $7.4 million for the nine months ended September 30, 2025 and no revenue. Cash and cash equivalents were roughly $0.9 million against current liabilities of about $2.9 million, including $1.6 million of convertible debt due within a year, and large long-term contingent payment obligations. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern without new licensing wins, successful litigation outcomes or additional financing.